Center for Cancer Imaging

East Melbourne, Australia

Center for Cancer Imaging

East Melbourne, Australia
SEARCH FILTERS
Time filter
Source Type

Bengtsson T.,Genentech | Hicks R.J.,Center for Cancer Imaging | Peterson A.,Genentech | Port R.E.,Genentech
Journal of Nuclear Medicine | Year: 2012

This study assesses the predictive value of 18F-FDG PET for overall survival in lung cancer patients treated with a targeted drug. Methods: 18F-FDG PET was performed in 125 second- or thirdline non-small cell lung cancer (NSCLC) patients with a baseline Eastern Cooperative Oncology Group performance status less than 3 before treatment with erlotinib (150 mg daily) and 2 wk into treatment. The predictive value of 18F-FDG PET, clinical parameters, and epithelial growth factor receptor (EGFR) mutation status for survival duration was evaluated by fitting accelerated failure time models. Results: New lesions on PET at 2 wk, EGFR mutation status, performance status, and baseline tumor burden were independent and significant predictors of overall survival. Reduction of maximum standardized uptake value by at least 35% was predictive of survival only when EGFR mutation status was not accounted for. Conclusion: 18F-FDG PET in second- or third-line NSCLC patients at 2 wk after starting treatment with erlotinib carries information about overall survival. Parametric survival modeling enables a quantitative assessment of the predictive value of 18F-FDG PET in the context of clinical and laboratory information. New-lesion status by 18F-FDG PET at 2 wk is a potential surrogate biomarker for survival in NSCLC. Copyright © 2012 by the Society of Nuclear Medicine, Inc.


Lau W.F.E.,University of Melbourne | Lau W.F.E.,Center for Cancer Imaging | Ware R.,Center for Cancer Imaging | Herth F.J.F.,University of Heidelberg
Respirology | Year: 2015

The global epidemic of lung cancer shows no signs of abating. It is generally accepted that accurate and cost-efficient diagnostic evaluation is the first important step to achieve the best outcomes of treatment. This is true in the context of disease confirmation, treatment planning, treatment monitoring, detection of and management of treatment failure or prognostication. Fortunately, major advances in the diagnostic evaluation of lung cancer have been made in the past three decades allowing more patients to get the appropriate treatment at the right time. This paper outlines how computed tomography, positron emission tomography/computed tomography and endobronchial ultrasound contribute to lung cancer management and discuss their strengths and weaknesses and their complimentary roles at different stages of lung cancer management. Due to financial constraint and reimbursement restrictions, not all clinically important advances in the diagnostic evaluation of lung cancer have been readily accepted into routine clinical care. This enforces the need to maintain ongoing dialogue between cancer clinicians, imaging specialists and health-care economists. © 2015 Asian Pacific Society of Respirology.


Hofman M.S.,Center for Cancer Imaging | Hofman M.S.,Peter MacCallum Cancer Center | Hofman M.S.,University of Melbourne | Eddie Lau W.F.,Center for Cancer Imaging | And 4 more authors.
Radiographics | Year: 2015

Gallium 68 (68Ga) 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA)–octreotate (DOTATATE, GaTate) positron emission tomography (PET)/computed tomography (CT) is an imaging technique for detecting and characterizing neuroendocrine tumors (NETs). GaTate, a somatostatin analog, has recently been accorded orphan drug status by the U.S. Food and Drug Administration, thereby increasing interest in and availability of this radiotracer. GaTate PET/CT allows whole-body imaging of cell surface expression of somatostatin receptors (SSTRs) and is rapidly evolving as the new imaging standard of reference for the detection and characterization of NETs. The authors discuss the normal appearance at GaTate PET/CT and the utility of this modality in a variety of these tumors, including gastrointestinal, pancreatic, and bronchial NETs as well as pheochromocytoma, paraganglioma, meningioma, and oncogenic osteomalacia. In addition, they discuss potential causes of false-positive findings, including pancreatic uncinate process activity, inflammation, osteoblastic activity, and splenosis. They also highlight the complementary role of 2-[fluorine-18]fluoro-2-deoxy-d-glucose (FDG) PET/CT, including the advantages of using both GaTate PET/CT and FDG PET/CT to evaluate sites of well- and poorly differentiated disease. The use of GaTate PET/CT together with FDG PET/CT allows identification of tumor heterogeneity, which provides prognostic information and can be pivotal in guiding biopsy. It also allows optimal patient management, including theranostic application of peptide receptor radionuclide therapy, and the restaging of patients following therapy. © RSNA, 2015.


Campbell B.A.,Peter MacCallum Cancer Center | Hornby C.,Peter MacCallum Cancer Center | Cunninghame J.,Peter MacCallum Cancer Center | Burns M.,Peter MacCallum Cancer Center | And 7 more authors.
Annals of Oncology | Year: 2012

Background: Chemotherapy plus radiotherapy is the standard of care for patients with limited stage Hodgkin lymphoma (HL). Radiotherapy is evolving from involved field radiotherapy (IFRT) to involved node radiotherapy (INRT) to decrease radiotherapy-related morbidity. In the absence of long-term toxicity data, dose-volume metrics of organs at risk (OAR) provide a surrogate measure of toxicity risk. Patients and methods: Ten female patients with stage I-IIA supradiaphragmatic HL were randomly selected. All patients had pre-chemotherapy computerised tomography (CT) and CT-positron emission tomography staging. Using CT planning, three radiotherapy plans were produced per patient: (i) IFRT, (ii) INRT using parallel-opposed beams and (iii) INRT using volumetric modulated arc therapy (VMAT). Radiotherapy dose was 30.6 Gy in 1.8 Gy fractions. OAR evaluated were lungs, breasts, thyroid, heart and coronary arteries. Results: Compared with IFRT, INRT significantly reduced mean doses to lungs (P < 0.01), breasts (P < 0.01), thyroid (P < 0.01) and heart (P < 0.01), on Wilcoxon testing. Compared with conventional INRT, VMAT improved dose conformality but increased low-dose radiation exposure to lungs and breasts. VMAT reduced the heart volume receiving 30 Gy (V30) by 85%. Conclusions: Reduction from IFRT to INRT decreased the volumes of lungs, breasts and thyroid receiving high-dose radiation, suggesting the potential to reduce long-term second malignancy risks. VMAT may be useful for patients with pre-existing heart disease by minimising further cardiac toxicity risks. © The Author 2011. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.


Tomaszewski J.M.,Peter MacCallum Cancer Center | Lau E.,Center for Cancer Imaging | Lau E.,University of Melbourne | Corry J.,Peter MacCallum Cancer Center | Corry J.,University of Melbourne
American Journal of Otolaryngology - Head and Neck Medicine and Surgery | Year: 2014

Purpose Cutaneous squamous cell carcinoma (cSCC) behaves aggressively in patients with chronic lymphocytic leukemia (CLL). Lymphadenopathy due to CLL can obscure the clinical and radiological assessment of nodal involvement by cSCC. This study aimed to evaluate whether functional imaging with positron emission tomography (PET)/computed tomography (CT) may clarify the clinical picture. Methods Five consecutive patients with cSCC and CLL who had a PET/CT scan for the purposes of cSCC staging between July 2000 and July 2010 were analyzed. PET/CT findings were compared to histopathology from subsequent neck dissection. Results PET/CT can distinguish nodal cSCC from leukemic infiltration with high specificity, allowing prompt appropriate management of nodal disease. Conclusions PET/CT is a promising modality for nodal staging in patients with cSCC and CLL, with the potential to improve outcomes in this poor prognosis group. Larger confirmatory studies are needed.


Barber T.W.,Center for Cancer Imaging | Hofman M.S.,Center for Cancer Imaging | Hofman M.S.,University of Melbourne | Thomson B.N.J.,University of Melbourne | And 3 more authors.
European Journal of Surgical Oncology | Year: 2012

Aims: To assess the clinical utility of peptide receptor chemoradionuclide therapy (PRCRT) using 177Lu-octreotate (LuTate) with concurrent 5FU chemotherapy in patients with inoperable primary pancreatic and duodenal neuroendocrine tumours (NETs). Methods: Between December 2006 and October 2009, five patients with progressive inoperable pancreatic and duodenal NETs without distant metastatic disease or with a potentially resectable solitary distant metastasis were treated with PRCRT; in combination with external beam radiotherapy in one case. Patients were followed up three months post-treatment with somatostatin receptor scintigraphy, radiology, biochemical markers and clinical assessment. Radiological response classification was defined by Response Evaluation Criteria in Solid Tumours (RECIST) with the addition of a minor response (MR; 10-30% size reduction) classification. Long-term follow up was performed until July 2011. Results: At three months post-treatment, all five patients had a scintigraphic response, four had a radiological response and three of the four symptomatic patients responded clinically. All five patients had an ongoing treatment response beyond three months including one where further tumour shrinkage facilitated curative surgery. All five patients are alive with 12-42 months of follow-up post-treatment. Conclusion: PRCRT can be effective in inoperable pancreatic and duodenal neuroendocrine tumours and may play a role as neoadjuvant therapy in this patient group. © 2011 Elsevier Ltd. All rights reserved.


Hofman M.S.,Center for Cancer Imaging | Hofman M.S.,University of Melbourne | Hicks R.J.,Center for Cancer Imaging | Hicks R.J.,University of Melbourne
Best Practice and Research: Clinical Haematology | Year: 2011

Imaging contributes to management of follicular lymphoma (FL) through guiding biopsy, determining disease stage and assessing therapeutic response. Molecular imaging with positron emission tomography (PET), especially when combined with computer tomography (PET/CT), is more accurate than conventional imaging and extends the role of imaging to lesion characterisation, including non-invasive assessment of high-grade transformation. There is strong data to support the use of FDG PET/CT for primary staging, resulting in significant management change. In patients with early stage follicular lymphoma (stage I or II), there is a clear role for PET/CT to avoid futile involved-field radiotherapy in patients with widespread disease and to optimise the treatment field in patients with confirmed localised disease. For restaging, use of PET/CT allows discrimination between scar tissue and viable tumour in residual masses. Molecular imaging is likely to play an increasing role in selection of patients for specific treatments and in prognostic stratification. © 2011 Elsevier Ltd. All rights reserved.


Hofman M.S.,Center for Cancer Imaging
Discovery medicine | Year: 2012

Molecular imaging is changing diagnostic and treatment paradigms in patients with neuroendocrine tumors through its ability to non-invasively characterize disease, supplementing the traditional role of using imaging for localizing and measuring disease. For patients with metastatic disease, there is an increasing range of therapies but these must be individualized to the specific subtype of tumor expressed, which varies in aggressiveness from well to poorly differentiated phenotypes. Positron emission tomography (PET) is now able to characterize these subtypes through its ability to quantify somatostatin receptor cell surface (SSTR) expression and glycolytic metabolism with SSTR and fluorodeoxyglucose (FDG) PET, respectively. The ability to perform this as a whole body study is highlighting the limitations of relying on histopathology obtained from a single site. Through earlier diagnosis, improved selection of the most appropriate therapy and better assessment of therapeutic response for an individual patient, molecular imaging is improving the outcome for patients with NET.


Hicks R.J.,University of Melbourne | Hicks R.J.,Center for Cancer Imaging
Cancer Imaging | Year: 2010

Imaging of neuroendocrine tumours (NET) poses significant challenges because of the heterogeneous biology of the tumours that are represented by this class of neoplasia. NET can range from benign lesions to highly aggressive cancers. Structural imaging techniques have suboptimal sensitivity in most published series and diagnosis is often delayed until metastatic disease is present. Current guidelines emphasise the importance of functional imaging for evaluating the extent of NET. The mainstay of this type of imaging has been somatostatin receptor scintigraphy (SRS) with [111In] diethylenetriaminepentaacetic acid-octreotide (OctreoscanTM). Routine use of single-photon emission computed tomography (SPECT) and particularly of hybrid SPECT/computed tomography (CT) has significantly improved localisation of tumour sites and evaluation of somatostatin receptor (SSTR) expression, which is important for predicting the likelihood of response to somatostatin analogues (SSA). Positron emission tomography (PET) can also now be used for evaluating SSTR expression. There are a number of peptides that have been evaluated but [68Ga]tetraazocyclodecanetetraacetic acid (DOTA)-octreotate (GaTate) PET/CT, which has been shown to be significantly more sensitive for detecting small lesions than OctreoscanTM, is now probably the preferred agent because high uptake in known sites of disease provides a diagnostic pair for assessing suitability of patients for [177Lu]DOTAoctreotate (LuTate) peptide receptor radionuclide therapy (PRRT). A range of other radiolabelled SSA has also been used for PRRT. Lesions without SSTR expression require alternative imaging and therapeutic strategies. Although fluorodeoxyglucose (FDG) uptake in low-grade NET is not generally increased relative to normal tissues, the loss of differentiation that often accompanies loss of SSTR expression may be associated with a significant increase in glycolytic metabolism and an accompanying improvement in the diagnostic sensitivity of FDG PET/CT. High FDG avidity is associated with a poorer prognosis but increases the likelihood of response to chemotherapy. Functioning tumours also require substrates for their secreted products. This can be exploited for NET imaging with amine precursor uptake being imaged using [18F]3,4-dihydrophenylalanine and serotonin-secreting tumours being sensitively detected using [11C]5-hydroxytryptamine. Both these agents are suitable for imaging with PET. [123I]meta-Iodo-benzyl-guanidine (MIBG) SPECT/CT may also be useful as a staging technique, particularly for NET of the sympathetic neuronal chain, and can identify patients who may be suitable for [131I]MIBG therapy. In the future, paradigms guided by clinical and biopsy features should allow personalised imaging paradigms aligned to therapeutic options. © 2009 International Cancer Imaging Society.


Health technology assessment (HTA) has the objective of providing individual patients, clinicians, and funding bodies with the highest-quality information on the net patient benefits and cost effectiveness of medical interventions. Founded on systematic reviews of the available evidence, HTA aims to reduce bias and thereby provide a more valid evaluation of the benefits of new medical interventions than the primary studies themselves. Competing with the traditional role of medical experts, HTA agencies have gained considerable influence over public opinion and policy. The fundamental tenets of evidence-based medicine mandate that this influence should be used first and foremost for the benefit of patients. Over nearly 2 decades, multiple HTA systematic reviews in many countries have discredited most or all of the evidence pertaining to the ability of PET to improve patient-important outcomes. These determinations have delayed, restricted, and, in many cases, prevented access to this technology, especially by cancer patients. HTA systematic review findings are very much at variance with the opinion of clinicians. Our scrutiny of these reviews, benchmarking them against the core values of science and evidence-based medicine, has revealed errors of fact, inappropriate exclusion of pertinent data, and injudicious appraisal of the clinical relevance of evidence, potentially introducing bias into these reviews and compromising the validity of their conclusions about the net patient benefits of PET. We believe that our findings mandate that the molecular imaging community actively engage institutionalized HTA agencies to ensure appropriate representation of our primary data and adherence to the highest principles of evidence-based medicine. Copyright © 2011 by the Society of Nuclear Medicine, Inc.

Loading Center for Cancer Imaging collaborators
Loading Center for Cancer Imaging collaborators